Summarized by Masters of Longevity from Longevity Technology.
New clinical trial and screening updates on treatments and diagnostics for serious lung and heart conditions, with practical implications for clinicians and patients.
Key Takeaways
- A large Phase 3 trial reported ralinepag produced meaningful clinical improvement in lower-risk pulmonary arterial hypertension patients.
- Nebulized treprostinil improved lung function and reduced serious exacerbations in idiopathic pulmonary fibrosis with a clear dose-response.
- Early PHINDER screening data indicate standard echocardiography may miss pulmonary hypertension in patients with interstitial lung disease.
